Ignite Creation Date:
2024-10-26 @ 3:38 PM
Last Modification Date:
2024-10-26 @ 3:38 PM
Study NCT ID:
NCT06564259
Status:
COMPLETED
Last Update Posted:
None
First Post:
2024-08-18
Brief Title:
Relationship Between Serum β2-Microglobulin and Infiltration of CD8 in the Tumor Tissue of Hodgkins Lymphoma Patients
Sponsor:
None
Organization:
None
Study Overview
Official Title:
The Relationship Between Serum Beta-2 Microglobulin sB2M Levels and CD8 Cell Infiltration in Hodgkin Lymphoma Tissues Impact on Chemotherapy Outcomes
Status:
COMPLETED
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
In newly diagnosed Hodgkin lymphoma patients pre-treatment Beta-2 Microglobulin B2M levels will be measured A thorough baseline assessment will be performed using CT imaging and tumor tissue samples will be collected for Immunohistochemical IHC analysis to quantify CD8 cell infiltration Patients will be closely monitored throughout their treatment with a follow-up CT scan at the end of therapy to evaluate therapeutic response This study aims to investigate the correlation between pre-treatment B2M levels and CD8 immune cell infiltration in tumor tissues assessing their potential as predictive markers for chemotherapy response
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None